


## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
4-20921B  
APPLICATION NO.  
09/202,805  
APPLICANT  
WAGNER ET AL.  
FILING DATE  
May 7, 1999

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
SONB	AA	4,353,887	10/12/82	Hess et al.	424	15	
SONB	AB	5,399,578	3/21/95	Bühlmayer et al.	514	381	
SONB	AC	5,464,854	11/7/95	dePadova	514	381	
SONB	AD	5,486,364	1/23/96	King et al.	424	488	
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
SONB	AM	11 490 ✓	5/28/80	EP (Abstract only)			<input type="checkbox"/>	<input type="checkbox"/>
SONB	AN	2421 273 ✓	11/14/74	Germany (Abstract only)			<input type="checkbox"/>	<input type="checkbox"/>
SONB	AO	396 335A ✓	11/7/90	EP (Abstract only)			<input type="checkbox"/>	<input type="checkbox"/>
SONB	AP	70 127 ✓	1/19/83	EP (Abstract only)			<input type="checkbox"/>	<input type="checkbox"/>
SONB	AQ	94 09778	5/11/94	W/O			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

SONB	AR	"Hydrochlorothiazide" - Martindale 89 pp. 991-993
SONB	AS	"Innovatives Antihypertensives," Therapiewoche 36, pp. 1982-1985 (1996)
SONB	AT	Chemical Abstracts 124:220073 (1996)

EXAMINER

Liliane DiNico Bana


DATE CONSIDERED

January 21, 2000

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)



ATTY. DOCKET NO.  
4-20921B  
APPLICATION NO.  
09/202,805  
APPLICANT  
WAGNER ET AL.  
FILING DATE  
May 7, 1999

Group

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

SeNB3	AA	DIALOG: Derwent Drug File - Abstract AN:96-09445 (1996)
SeNB3	AB	DIALOG: Drug Data Report - Abstract AN 185987 (1992)
SeNB3	AC	DIALOG: JICST EPlus - Abstract AN:96A0157433 (1995)
SeNB3	AD	EMBASE: Abstract 96015489 (1995)
SeNB3	AE	EMBASE: Abstract AN-96-374183 (1996)
SeNB3	AF	EMBASE: Abstract AN-97-027003 (1997)
SeNB3	AG	Fujimura Y. et al., "Antihypertensive effect of a combination of Valsartan . . .", YAKURI TO CHIRYO, Vol. 23, No. 12, 1995, pp. 3241-3247
SeNB3	AH	Grun, A. et al., "A comparison of the efficacy and tolerability . . .", European Heart Journal, Vol. 161, No. Sup. (1995), p. 61
SeNB3	AI	Lachman, L. et al., "The Theory and Practice of Industrial Pharmacy," Lea & Febiger, 1986, pp. 318-320
SeNB3	AJ	Markham, A. et al., "Valsartan: a review of its pharmacology and therapeutic use . . .", DRUGS, Vol. 54, No. 2, (1997) pp. 299-311
SeNB3	AK	TOXLIT: Abstract AN-96:69983 (1995)
	AL	
	AM	
	AN	

EXAMINER

*Silviana Di Nola Baro*


DATE CONSIDERED

*January 21, 2000*

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)



ATTY. DOCKET NO.  
4-20921B  
APPLICATION NO.  
09/202,805  
APPLICANT  
WAGNER ET AL.  
FILING DATE  
May 7, 1999

Group

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>Long</i>	AA	95 24901	9/21/95	<del>PCT International</del> WO	—	—	<input type="checkbox"/>	<input type="checkbox"/>
<i>Long</i>	AB	95 28927	11/2/95	<del>PCT International</del> WO	—	—	<input type="checkbox"/>	<input type="checkbox"/>
<i>Long</i>	AC	95 29674	11/9/95	<del>PCT International</del> WO	—	—	<input type="checkbox"/>	<input type="checkbox"/>
	AD						<input type="checkbox"/>	<input type="checkbox"/>
	AE						<input type="checkbox"/>	<input type="checkbox"/>
	AF						<input type="checkbox"/>	<input type="checkbox"/>
	AG						<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>
	AI						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>
	AL						<input type="checkbox"/>	<input type="checkbox"/>
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>
	AR						<input type="checkbox"/>	<input type="checkbox"/>
	AS						<input type="checkbox"/>	<input type="checkbox"/>
	AT						<input type="checkbox"/>	<input type="checkbox"/>
	AU						<input type="checkbox"/>	<input type="checkbox"/>
	AV						<input type="checkbox"/>	<input type="checkbox"/>
	AW						<input type="checkbox"/>	<input type="checkbox"/>
	AX						<input type="checkbox"/>	<input type="checkbox"/>
	AY						<input type="checkbox"/>	<input type="checkbox"/>
	AZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

*Liliane DiNobilia*

DATE CONSIDERED

*January 21, 2000*

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.